The role of reproductive hormones in postpartum depression

CNS Spectrums

Volumn 20, Issue 1, 2015, Pages 48-59

  Schiller, Crystal Edler ^a   Meltzer Brody, Samantha ^a   Rubinow, David R ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

allopregnanolone; estrogen; postpartum depression; progesterone

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; CYCLIC AMP; ESTRADIOL; NEUROTROPHIN RECEPTOR; OXYTOCIN; PROGESTERONE; PROLACTIN; PROTEIN TYROSINE KINASE A; THYROXINE BINDING GLOBULIN; TUMOR NECROSIS FACTOR ALPHA; ELTANOLONE; ESTROGEN;

BRAIN BLOOD FLOW; DISEASE PREDISPOSITION; EMOTIONALITY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HORMONE ACTION; HORMONE BLOOD LEVEL; HORMONE DETERMINATION; HORMONE SENSITIVITY; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; NEUROBIOLOGY; NONHUMAN; OVARIECTOMY; PATHOPHYSIOLOGY; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; PSYCHOLOGICAL WELL BEING; PUERPERAL DEPRESSION; REVIEW; THYROID FUNCTION; ANIMAL; DEPRESSION, POSTPARTUM; FEMALE; METABOLISM; PREGNANCY;

ANIMALS; DEPRESSION, POSTPARTUM; ESTROGENS; FEMALE; HUMANS; PREGNANCY; PREGNANOLONE; PROGESTERONE;

EID: 84925145668     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852914000480     Document Type: Review

References (157)

1. Gavin NI, Gaynes BN, Lohr KN, Meltzer-Brody S, Gartlehner G, Swinson T. Perinatal depression: A systematic review of prevalence and incidence. Obstet Gynecol. 2005; 106(5 Pt 1): 1071-1083.
2. Hendrick V, Altshuler LL, Suri R. Hormonal changes in the postpartum and implications for postpartum depression. Psychosomatics. 1998; 39(2): 93-101.
3. BlochM, Schmidt PJ,DanaceauM,Murphy J,Nieman L, Rubinow DR. Effects of gonadal steroids in women with a history of postpartum depression. Am J Psychiatry. 2000; 157(6): 924-930.
4. Galea LA, Wide JK, Barr AM. Estradiol alleviates depressive-like symptoms in a novel animal model of post-partum depression. Behav Brain Res. 2001; 122(1): 1-9.
5. Gregoire AJ, Kumar R, Everitt B, Henderson AF, Studd JW. Transdermal oestrogen for treatment of severe postnatal depression. Lancet. 1996; 347(9006): 930-933.
6. Sichel DA, Cohen LS, Robertson LM, Ruttenberg A, Rosenbaum JF. Prophylactic estrogen in recurrent postpartum affective disorder. Biol Psychiatry. 1995; 38(12): 814-818.
7. Stoffel EC, Craft RM. Ovarian hormone withdrawal-induced "depression" in female rats. Physiol Behav. 2004; 83(3): 505-513.
8. Suda S, Segi-Nishida E, Newton SS, Duman RS. A postpartum model in rat: Behavioral and gene expression changes induced by ovarian steroid deprivation. Biol Psychiatry. 2008; 64(4): 311-319.
9. Buckwalter JG, Stanczyk FZ, McCleary CA, et al. Pregnancy, the postpartum, and steroid hormones: Effects on cognition and mood. Psychoneuroendocrinology. 1999; 24(1): 69-84.
10. Heidrich A, Schleyer M, Spingler H, et al. Postpartum blues: Relationship between not-protein bound steroid hormones in plasma and postpartum mood changes. J Affect Disord. 1994; 30(2): 93-98.
11. O'Hara MW, Schlechte JA, Lewis DA, Varner MW. Controlled prospective study of postpartum mood disorders: Psychological, environmental, and hormonal variables. J Abnorm Psychol. 1991; 100(1): 63-73.
12. Ahokas A, Kaukoranta J, Wahlbeck K, Aito M. Estrogen deficiency in severe postpartum depression: Successful treatment with sublingual physiologic 17beta-estradiol: A preliminary study. J Clin Psychiatry. 2001; 62(5): 332-336.
13. Beck CT. Predictors of postpartum depression: An update. Nurs Res. 2001; 50(5): 275-285.
14. Collins NL, Dunkel-Schetter C, Lobel M, Scrimshaw SC. Social support in pregnancy: Psychosocial correlates of birth outcomes and postpartum depression. J Pers Soc Psychol. 1993; 65(6): 1243-1258.
15. O'Hara MW, Swain AM. Rates and risk of postpartum depression-a meta-analysis. Int Rev Psychiatry. 1996; 8(1): 37-54.
16. Bloch M, Rotenberg N, Koren D, Klein E. Risk factors for early postpartum depressive symptoms. Gen Hosp Psychiatry. 2006; 28(1): 3-8.
17. O'Hara MW, Neunaber DJ, Zekoski EM. Prospective study of postpartum depression: Prevalence, course, and predictive factors. J Abnorm Psychol. 1984; 93(2): 158-171.
18. Schiller CE, O'Hara MW, Rubinow DR, Johnson AK. Estradiol modulates anhedonia and behavioral despair in rats and negative affect in a subgroup of women at high risk for postpartum depression. Physiol Behav. 2013; 119: 137-144.
19. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington, VA: American Psychiatric Publishing; 2013.
20. Bernstein IH, Rush AJ, Yonkers K, et al. Symptom features of postpartum depression: Are they distinct? Depress Anxiety. 2008; 25(1): 20-26.
21. Wisner KL, Sit DY, McShea MC, et al. Onset timing, thoughts of selfharm, and diagnoses in postpartum women with screen-positive depression findings. JAMA Psychiatry. 2013; 70(5): 490-498.
22. O'Hara MW. Postpartum Depression: Causes and Consequences. New York: Springer-Verlag; 1995.
23. Vesga-Lopez O, Blanco C, Keyes K, Olfson M, Grant BF, Hasin DS. Psychiatric disorders in pregnant and postpartum women in the United States. Arch Gen Psychiatry. 2008; 65(7): 805-815.
24. Sit D, Rothschild AJ, Wisner KL. A review of postpartum psychosis. J Womens Health (Larchmt). 2006; 15(4): 352-368.
25. Wisner KL, Peindl K, Hanusa BH. Symptomatology of affective and psychotic llnesses related to childbearing. J Affect Disord. 1994; 30(2): 77-87.
26. Brockington IF, Cernik KF, Schofield EM, Downing AR, Francis AF, Keelan C. Puerperal psychosis: Phenomena and diagnosis. Arch Gen Psychiatry. 1981; 38(7): 829-833.
27. Kendell RE, Chalmers JC, Platz C. Epidemiology of puerperal psychoses. Br J Psychiatry. 1987; 150(5): 662-673.
28. Forty L, Jones L, Macgregor S, et al. Familiality of postpartum depression in unipolar disorder: Results of a family study. Am J Psychiatry. 2006; 163(9): 1549-1553.
29. Deligiannidis KM, Sikoglu EM, Shaffer SA, et al. GABAergic neuroactive steroids and resting-state functional connectivity in postpartum depression: A preliminary study. J Psychiatr Res. 2013; 47(6): 816-828.
30. Sohrabji F, Miranda RC, Toran-Allerand CD. Estrogen differentially regulates estrogen and nerve growth factor receptor mRNAs in adult sensory neurons. J Neurosci. 1994; 14(2): 459-471.
31. Shimizu E, Hashimoto K, Okamura N, et al. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry. 2003; 54(1): 70-75.
32. Zhou Y, Watters JJ, Dorsa DM. Estrogen rapidly induces the phosphorylation of the cAMP response element binding protein in rat brain. Endocrinology. 1996; 137(5): 2163-2166.
33. Sohrabji F, Greene LA, Miranda RC, Toran-Allerand CD. Reciprocal regulation of estrogen and NGF receptors by their ligands in PC12 cells. J Neurobiol. 1994; 25(8): 974-988.
34. Cardona-Gomez P, Perez M, Avila J, Garcia-Segura L, Wandosell F. Estradiol inhibits GSK3 and regulates interaction of estrogen receptors, GSK3, and beta-catenin in the hippocampus. Mol Cell Neurosci. 2004; 25(3): 363-373.
35. Finocchi C, Ferrari M. Female reproductive steroids and neuronal excitability. Neurol Sci. 2011; 32(Suppl 1): S31-S35.
36. Pluchino N, Russo M, Santoro AN, Litta P, Cela V, Genazzani AR. Steroid hormones and BDNF. Neuroscience. 2013; 239: 271-279.
37. Rubinow DR, Girdler SS. Hormones, heart disease, and health: Individualized medicine versus throwing the baby out with the bathwater. Depress Anxiety. 2011; 28(4): 282-296.
38. Berman KF, Schmidt PJ, Rubinow DR, et al. Modulation of cognition-specific cortical activity by gonadal steroids: A positronemission tomography study in women. Proc Natl Acad Sci U S A. 1997; 94(16): 8836-8841.
39. Goldstein JM, Jerram M, Poldrack R, et al. Hormonal cycle modulates arousal circuitry in women using functional magnetic resonance imaging. J Neurosci. 2005; 25(40): 9309-9316.
40. Protopopescu X, PanH, Altemus M, et al. Orbitofrontal cortex activity related to emotional processing changes across the menstrual cycle. Proc Natl Acad Sci U S A. 2005; 102(44): 16060-16065.
41. Dreher JC, Schmidt PJ, Kohn P, Furman D, Rubinow D, Berman KF. Menstrual cycle phase modulates reward-related neural function in women. Proc Natl Acad Sci U S A. 2007; 104(7): 2465-2470.
42. Santin AP, Furlanetto TW. Role of estrogen in thyroid function and growth regulation. J Thyroid Res. 2011; 2011: E875125.
43. Schumacher M, Coirini H, Pfaff DW, McEwen BS. Behavioral effects of progesterone associated with rapid modulation of oxytocin receptors. Science. 1990; 250(4981): 691-694.
44. Walf AA, Frye CA. Antianxiety and antidepressive behavior produced by physiological estradiol regimen may be modulated by hypothalamic-pituitary-adrenal axis activity. Neuropsychopharmacology. 2005; 30(7): 1288-1301.
45. Roca CA, Schmidt PJ, Altemus M, et al. Differential menstrual cycle regulation of hypothalamic-pituitary-adrenal axis in women with premenstrual syndrome and controls. J Clin Endocrinol Metab. 2003; 88(7): 3057-3063.
46. Butts CL, Sternberg EM. Neuroendocrine factors alter host defense by modulating immune function. Cell Immunol. 2008; 252(1-2): 7-15.
47. Bunevicius R,Kusminskas L,MickuvieneN, BuneviciusA, PedersenCA, Pop VJM. Depressive disorder and thyroid axis functioning during pregnancy. World J Biol Psychiatry. 2009; 10(4): 324-329.
48. Placidi GPA, Boldrini M, Patronelli A, et al. Prevalence of psychiatric disorders in thyroid diseased patients. Neuropsychobiology. 1998; 38(4): 222-225.
49. Gulseren S,Gulseren L,Hekimsoy Z, Cetinay P,OzenC, Tokatlioglu B. Depression, anxiety, health-related quality of life, and disability in patients with overt and subclinical thyroid dysfunction. Arch Med Res. 2006; 37(1): 133-139.
50. Berent D, Zboralski K, Orzechowska A, Ga?ecki P. Thyroid hormones association with depression severity and clinical outcome in patients with major depressive disorder. Mol Biol Rep. 2014; 41(4): 2419-2425.
51. Nemeroff CB, Simon JS, Haggerty JJ Jr, Evans DL. Antithyroid antibodies in depressed patients. Am J Psychiatry. 1985; 142(7): 840-843.
52. Cooper-Kazaz R, Lerer B. Efficacy and safety of triiodothyronine supplementation in patients with major depressive disorder treated with specific serotonin reuptake inhibitors. Int J Neuropsychopharmacol. 2008; 11(5): 685-699.
53. Cooper-Kazaz R, Apter JT, Cohen R, et al. Combined treatment with sertraline and liothyronine in major depression: A randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry. 2007; 64(6): 679-688.
54. Ben-Rafael Z, Struass JF 3rd, Arendash-Durand B, Mastroianni L Jr, Flickinger GL. Changes in thyroid function tests and sex hormone binding globulin associated with treatment by gonadotropin. Fertil Steril. 1987; 48(2): 318-320.
55. Arafah BM. Increased need for thyroxine in women with hypothyroidism during estrogen therapy. N Engl J Med. 2001; 344(23): 1743-1749.
56. Vaidya B, Anthony S, Bilous M, et al. Detection of thyroid dysfunction in early pregnancy: Universal screening or targeted high-risk case finding? J Clin Endocrinol Metab. 2007; 92(1): 203-207.
57. Pedersen CA, Johnson JL, Silva S, et al. Antenatal thyroid correlates of postpartum depression. Psychoneuroendocrinology. 2007; 32(3): 235-245.
58. Pedersen CA, Stern RA, Pate J, Senger MA, Bowes WA, Mason GA. Thyroid and adrenal measures during late pregnancy and the puerperium in women who have been major depressed or who become dysphoric postpartum. J Affect Disord. 1993; 29(2-3): 201-211.
59. Bloch M, Daly RC, Rubinow DR. Endocrine factors in the etiology of postpartum depression. Compr Psychiatry. 2003; 44(3): 234-246.
60. Albacar G, Sans T, Martín-Santos R, et al. Thyroid function 48h after delivery as a marker for subsequent postpartum depression. Psychoneuroendocrinology. 2010; 35(5): 738-742.
61. Kent GN, Stuckey BG, Allen JR, Lambert T, Gee V. Postpartum thyroid dysfunction: Clinical assessment and relationship to psychiatric affective morbidity. Clin Endocrinol (Oxf). 1999; 51(4): 429-438.
62. Stuebe AM, Grewen K, Pedersen CA, Propper C, Meltzer-Brody S. Failed lactation and perinatal depression: Common problems with shared neuroendocrine mechanisms? J Womens Health (Larchmt). 2012; 21(3): 264-272.
63. Stuebe AM, Grewen K, Meltzer-Brody S. Association between maternal mood and oxytocin response to breastfeeding. J Womens Health (Larchmt). 2013; 22(4): 352-361.
64. Amico JA, Crowley RS, Insel TR, Thomas A, O'Keefe JA. Effect of gonadal steroids upon hypothalamic oxytocin expression. Adv Exp Med Biol. 1995; 395: 23-35.
65. Broad KD, Kendrick KM, Sirinathsinghji DJS, Keverne EB. Changes in oxytocin immunoreactivity and mRNA expression in the sheep brain during pregnancy, parturition and lactation and in response to oestrogen and progesterone. JNeuroendocrinol. 1993; 5(4): 435-444.
66. Skrundz M, Bolten M, Nast I, Hellhammer DH, Meinlschmidt G. Plasma oxytocin concentration during pregnancy is associated with development of postpartum depression. Neuropsychopharmacology. 2011; 36(9): 1886-1893.
67. Apter-Levy Y, Feldman M, Vakart A, Ebstein RP, Feldman R. Impact of maternal depression across the first 6 years of life on the child's mental health, social engagement, and empathy: The moderating role of oxytocin. Am J Psychiatry. 2013; 170(10): 1161-1168.
68. Kim S, Soeken TA, Cromer SJ, Martinez SR, Hardy LR, Strathearn L. Oxytocin and postpartum depression: Delivering on what's known and what's not. Brain Res. 2014; 1580: 219-232.
69. Mah BL, Van IJzendoorn MH, Smith R, Bakermans-Kranenburg MJ. Oxytocin in postnatally depressed mothers: Its influence on mood and expressed emotion. Prog Neuropsychopharmacol Biol Psychiatry. 2013; 40: 267-272.
70. Nestler EJ, BarrotM, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM. Neurobiology of depression. Neuron. 2002; 34(1): 13-25.
71. HeimC, Newport DJ,WagnerD,WilcoxMM,Miller AH, Nemeroff CB. The role of early adverse experience and adulthood stress in the prediction of neuroendocrine stress reactivity in women: A multiple regression analysis. Depress Anxiety. 2002; 15(3): 117-125.
72. Records K, Rice MJ. A comparative study of postpartum depression in abused and nonabused women. Arch Psychiatr Nurs. 2005; 19(6): 281-290.
73. Ross LE, Dennis CL. The prevalence of postpartumdepression among women with substance use, an abuse history, or chronic illness: A systematic review.JWomensHealth(Larchmt). 2009; 18(4): 475-486.
74. Mastorakos G, Ilias I. Maternal and fetal hypothalamic-pituitaryadrenal axes during pregnancy and postpartum. Ann N Y Acad Sci. 2003; 997: 136-149.
75. Young EA. Glucocorticoid cascade hypothesis revisited: Role of gonadal steroids. Depression. 1995; 3(1-2): 20-27.
76. Vamvakopoulos NC, Chrousos GP. Evidence of direct estrogenic regulation of human corticotropin-releasing hormone gene expression: Potential implications for the sexual dimorphism of the stress response and immune/inflammatory reaction. J Clin Invest. 1993; 92(4): 1896-1902.
77. Jolley SN, Elmore S, Barnard KE, Carr DB. Dysregulation of the hypothalamic-pituitary-adrenal axis in postpartum depression. Biol Res Nurs. 2007; 8(3): 210-222.
78. Handley SL, Dunn TL, Waldron G, Baker JM. Tryptophan, cortisol and puerperal mood. Br J Psychiatry. 1980; 136(5): 498-508.
79. Corwin EJ, Pajer K. The psychoneuroimmunology of postpartum depression. J Womens Health (Larchmt). 2008; 17(9): 1529-1534.
80. Dowlati Y, Herrmann N, Swardfager W, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010; 67(5): 446-457.
81. Raison CL, Capuron L, Miller AH. Cytokines sing the blues: Inflammation and the pathogenesis of depression. Trends Immunol. 2006; 27(1): 24-31.
82. Cunningham M, Gilkeson G. Estrogen receptors in immunity and autoimmunity. Clin Rev Allergy Immunol. 2011; 40(1): 66-73.
83. Segman RH, Goltser-Dubner T, Weiner I, et al. Blood mononuclear cell gene expression signature of postpartum depression. Mol Psychiatry. 2010; 15(1): 93-100, 102.
84. Krause D, Jobst A, Kirchberg F, et al. Prenatal immunologic predictors of postpartum depressive symptoms: A prospective study for potential diagnostic markers. Eur Arch Psychiatry Clin Neurosci. In press. DOI: 10.1007/s00406-014-0494-8.
85. Blackmore ER,Moynihan JA, Rubinow DR, Pressman EK, GilchristM, O'Connor TG. Psychiatric symptoms and proinflammatory cytokines in pregnancy. Psychosom Med. 2011; 73(8): 656-663.
86. Blackmore ER, Groth SW, Chen DG, Gilchrist MA, O'Connor TG, Moynihan JA. Depressive symptoms and proinflammatory cytokines across the perinatal period in African American women. J Psychosom Obstet Gynaecol. 2013; 35(1): 8-15.
87. Okun ML, Luther J, Prather AA, Perel JM,Wisniewski S,Wisner KL. Changes in sleep quality, but not hormones predict time to postpartum depression recurrence. J Affect Disord. 2011; 130(3): 378-384.
88. Murphy-Eberenz K, Zandi PP, March D, et al. Is perinatal depression familial? J Affect Disord. 2006; 90(1): 49-55.
89. Treloar SA, Martin NG, Bucholz KK, Madden PA, Heath AC. Genetic influences on post-natal depressive symptoms: Findings from an Australian twin sample. Psychol Med. 1999; 29(3): 645-654.
90. Figueira P, Malloy-Diniz L, Campos SB, et al. An association study between the Val66Met polymorphism of the BDNF gene and postpartum depression. Arch Womens Ment Health. 2010; 13(3): 285-289.
91. Comasco E, Sylvén SM, Papadopoulos FC, Oreland L, Sundström-Poromaa I, Skalkidou A. Postpartum depressive symptoms and the BDNF Val66Met functional polymorphism: Effect of season of delivery. Arch Womens Ment Health. 2011; 14(6): 453-463.
92. Comasco E, Sylvén SM, Papadopoulos FC, Sundström-Poromaa I, Oreland L, Skalkidou A. Postpartum depression symptoms: A casecontrol study on monoaminergic functional polymorphisms and environmental stressors. Psychiatr Genet. 2011; 21(1): 19-28.
93. Alvim-Soares A,MirandaD,Campos SB, Figueira P, Romano-SilvaMA, CorreaH. Postpartumdepression symptoms associated with Val158Met COMT polymorphism. Arch Womens Ment Health. 2013; 16(4): 339-340.
94. Engineer N, Darwin L, Nishigandh D, Ngianga-Bakwin K, Smith SC, Grammatopoulos DK. Association of glucocorticoid and type 1 corticotropin-releasing hormone receptors gene variants and risk for depression during pregnancy and post-partum. J Psychiatr Res. 2013; 47(9): 1166-1173.
95. Binder EB, Newport DJ, Zach EB, et al. A serotonin transporter gene polymorphism predicts peripartum depressive symptoms in an atrisk psychiatric cohort. J Psychiatr Res. 2010; 44(10): 640-646.
96. Mitchell C, Notterman D, Brooks-Gunn J, et al. Role of mother's genes and environment in postpartum depression. Proc Natl Acad Sci U S A. 2011; 108(20): 8189-8193.
97. El-Ibiary SY, Hamilton SP, Abel R, Erdman CA, Robertson PA, Finley PR. A pilot study evaluating genetic and environmental factors for postpartum depression. Innov Clin Neurosci. 2013; 10(9-10): 15-22.
98. Costas J, Gratacòs M, Escaramís G, et al. Association study of 44 candidate genes with depressive and anxiety symptoms in postpartum women. J Psychiatr Res. 2010; 44(11): 717-724.
99. Pinsonneault JK, Sullivan D, Sadee W, Soares CN, Hampson E, Steiner M. Association study of the estrogen receptor gene ESR1 with postpartum depression-a pilot study. Arch Womens Ment Health. 2013; 16(6): 499-509.
100. Pinheiro RT, Coelho FM, Silva RA, et al. Association of a serotonin transporter gene polymorphism (5-HTTLPR) and stressful life events with postpartum depressive symptoms: A populationbased study. J Psychosom Obstet Gynaecol. 2013; 34(1): 29-33.
101. Mahon PB, Payne JL, MacKinnon DF, et al. Genome-wide linkage and follow-up association study of postpartum mood symptoms. Am J Psychiatry. 2009; 166(11): 1229-1237.
102. Alvim-Soares AM, Miranda DM, Campos SB, Figueira P, Correa H, Romano-Silva MA. HMNC1 gene polymorphism associated with postpartum depression. Rev Bras Psiquiatr. 2014; 36(1): 96-97.
103. Mehta D, Newport DJ, Frishman G, et al. Early predictive biomarkers for postpartum depression point to a role for estrogen receptor signaling. Psychol Med. 2014; 44(11): 2309-2322.
104. Guintivano J, Arad M, Gould TD, Payne JL, Kaminsky ZA. Antenatal prediction of postpartum depression with blood DNA methylation biomarkers. Mol Psychiatry. 2014; 19(5): 560-567.
105. Green AD, Barr AM, Galea LAM. Role of estradiol withdrawal in "anhedonic" sucrose consumption: A model of postpartum depression. Physiol Behav. 2009; 97(2): 259-265.
106. Bekku N, Yoshimura H. Animal model of menopausal depressivelike state in female mice: Prolongation of immobility time in the forced swimming test following ovariectomy. Psychopharmacology (Berl). 2005; 183(3): 300-307.
107. Bernardi M, Vergoni AV, Sandrini M, Tagliavini S, Bertolini A. Influence of ovariectomy, estradiol and progesterone on the behavior of mice in an experimental model of depression. Physiol Behav. 1989; 45(5): 1067-1068.
108. Estrada-Camarena E, Fernandez-Guasti A, Lopez-Rubalcava C. Antidepressant-like effect of different estrogenic compounds in the forced swimming test. Neuropsychopharmacology. 2003; 28(5): 830-838.
109. Walf AA, Rhodes ME, Frye CA. Antidepressant effects of ERbetaselective estrogen receptor modulators in the forced swim test. Pharmacol Biochem Behav. 2004; 78(3): 523-529.
110. Walf AA, Frye CA. A review and update of mechanisms of estrogen in the hippocampus and amygdala for anxiety and depression behavior. Neuropsychopharmacology. 2006; 31(6): 1097-1111.
111. Maayan R, Strous RD, Abou-Kaoud M, Weizman A. The effect of 17beta estradiol withdrawal on the level of brain and peripheral neurosteroids in ovarectomized rats. Neurosci Lett. 2005; 384(1-2): 156-161.
112. Bossé R, Rivest R, Di Paolo T. Ovariectomy and estradiol treatment affect the dopamine transporter and its gene expression in the rat brain. Brain Res Mol Brain Res. 1997; 46(1-2): 343-346.
113. Di Paolo T, Poyet P, Labrie F. Effect of prolactin and estradiol on rat striatal dopamine receptors. Life Sci. 1982; 31(25): 2921-2929.
114. Di Paolo T, Poyet P, Labrie F. Prolactin and estradiol increase striatal dopamine receptor density in intact, castrated and hypophysectomized rats. Prog Neuropsychopharmacol Biol Psychiatry. 1982; 6(4-6): 377-382.
115. Byrnes EM, Byrnes JJ, Bridges RS. Increased sensitivity of dopamine systems following reproductive experience in rats. Pharmacol Biochem Behav. 2001; 68(3): 481-489.
116. Wenzel A, Haugen EN, Jackson LC, Brendle JR. Anxiety symptoms and disorders at eight weeks postpartum. J Anxiety Disord. 2005; 19(3): 295-311.
117. Beckley EH, Finn DA. Inhibition of progesterone metabolism mimics the effect of progesterone withdrawal on forced swim test immobility. Pharmacol Biochem Behav. 2007; 87(4): 412-419.
118. Smith SS, Gong QH, Li X, et al. Withdrawal from 3?-OH-5?-pregnan-20-one using a pseudopregnancy model alters the kinetics of hippocampal GABAA-gated current and increases the GABAA receptor ?4 subunit in association with increased anxiety. J Neurosci. 1998; 18(14): 5275-5284.
119. Dennerstein L, Spencer-Gardner C, Gotts G, Brown JB, Smith MA, Burrows GD. Progesterone and the premenstrual syndrome: A double blind crossover trial. Br Med J (Clin Res Ed). 1985; 290(6482): 1617-1621.
120. Frye CA, Walf AA. Hippocampal 3?,5?-THP may alter depressive behavior of pregnant and lactating rats. Pharmacol Biochem Behav. 2004; 78(3): 531-540.
121. Chatzicharalampous C, Rizos D, Pliatsika P, et al. Reproductive hormones and postpartum mood disturbances in Greek women. Gynecol Endocrinol. 2010; 27(8): 543-550.
122. Silverman ME, Loudon H, Safier M, et al. Neural dysfunction in postpartum depression: An fMRI pilot study. CNS Spectr. 2007; 12(11): 853-862.
123. Moses-Kolko EL, Perlman SB, Wisner KL, James J, Saul AT, Phillips ML. Abnormally reduced dorsomedial prefrontal cortical activity and effective connectivity with amygdala in response to negative emotional faces in postpartum depression. Am J Psychiatry. 2010; 167(11): 1373-1380.
124. Moses-Kolko EL, Fraser D, Wisner KL, et al. Rapid habituation of ventral striatal response to reward receipt in postpartum depression. Biol Psychiatry. 2011; 70(4): 395-399.
125. Goodyer IM, Herbert J, Altham PM, Pearson J, Secher SM, Shiers HM. Adrenal secretion during major depression in 8-to 16-yearolds, I. Altered diurnal rhythms in salivary cortisol and dehydroepiandrosterone (DHEA) at presentation. Psychol Med. 1996; 26(2): 245-256.
126. Yaffe K, Ettinger B, Pressman A, et al. Neuropsychiatric function and dehydroepiandrosterone sulfate in elderly women: A prospective study. Biol Psychiatry. 1998; 43(9): 694-700.
127. Heuser I, Deuschle M, Luppa P, Schweiger U, Standhardt H, Weber B. Increased diurnal plasma concentrations of dehydroepiandrosterone in depressed patients. J Clin Endocrinol Metab. 1998; 83(9): 3130-3133.
128. Michael A, Jenaway A, Paykel ES, Herbert J. Altered salivary dehydroepiandrosterone levels in major depression in adults. Biol Psychiatry. 2000; 48(10): 989-995.
129. Schmidt PJ, Murphy JH, Haq N, Danaceau MA, St Clair L. Basal plasma hormone levels in depressed perimenopausal women. Psychoneuroendocrinology. 2002; 27(8): 907-920.
130. Wolkowitz OM, Reus VI, Keebler A, et al. Double-blind treatment of major depression with dehydroepiandrosterone. Am J Psychiatry. 1999; 156(4): 646-649.
131. Schmidt P, Daly RC, Bloch M, et al. Dehydroepiandrosterone monotherapy in midlife-onset major and minor depression. Arch Gen Psychiatry. 2005; 62(2): 154-162.
132. Majewska MD, Harrison NL, Schwartz RD, Barker JL, Paul SM. Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor. Science. 1986; 232(4753): 1004-1007.
133. Bitran D, Hilvers RJ, Kellogg CK. Anxiolytic effects of 3?-hydroxy-5?[?]-pregnan-20-one: Endogenous metabolites of progesterone that are active at the GABAA receptor. Brain Res. 1991; 561(1): 157-161.
134. Wieland S, Lan NC, Mirasedeghi S, Gee KW. Anxiolytic activity of the progesterone metabolite 5?-pregnan-3?-ol-20-one. Brain Res. 1991; 565(2): 263-268.
135. Bitran D, Purdy RH, Kellog CK. Anxiolytic effect of progesterone is associated with increases in cortical alloprenanolone and GABAA receptor function. Pharmacol Biochem Behav. 1993; 45(2): 423-428.
136. Smith SS, Gong QH, Hsu FC, Markowitz RS, ffrench-Mullen JM, Li X. GABA(A) receptor alpha4 subunit suppression prevents withdrawal properties of an endogenous steroid. Nature. 1998; 392(6679): 926-930.
137. Uzunova V, Sheline Y, Davis JM, et al. Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Proc Natl Acad Sci U S A. 1998; 95(6): 3239-3244.
138. Romeo E, Ströhle A, Spalletta G, et al. Effects of antidepressant treatment on neuroactive steroids in major depression. Am J Psychiatry. 1998; 155(7): 910-913.
139. Ströhle A, Romeo E, Hermann B, et al. Concentrations of 3?-reduced neuroactive steroids and their precursors in plasma of patients with major depression and after clinical recovery. Biol Psychiatry. 1999; 45(3): 274-277.
140. Schüle C, Romeo E, Uzunov DP, et al. Influence of mirtazapine on plasma concentrations of neuroactive steroids in major depression and on 3?-hydroxysteroid dehydrogenase activity. Mol Psychiatry. 2005; 11(3): 261-272.
141. Eser D, Schüle C, Baghai TC, Romeo E, Rupprecht R. Neuroactive steroids in depression and anxiety disorders: Clinical studies. Neuroendocrinology. 2006; 84(4): 244-254.
142. Schüle C, Baghai TC, di Michele F, et al. Effects of combination treatment with mood stabilizers and mirtazapine on plasma concentrations of neuroactive steroids in depressed patients. Psychoneuroendocrinology. 2007; 32(6): 669-680.
143. Patchev VK, Shoaib M, Holsboer F, Almeida OFX. The neurosteroid tetrahydroprogesterone counteracts corticotropinreleasing hormone-induced anxiety and alters the release and gene expression of corticotropin-releasing hormone in the rat hypothalamus. Neuroscience. 1994; 62(1): 265-271.
144. Patchev VK, Hassan AHS, Holsboer F, Almeida OFX. The neurosteroid tetrahydroprogesterone attenuates the endocrine response to stress and exerts glucocorticoid-like effects on vasopressin gene transcription in the rat hypothalamus. Neuropsychopharmacology. 1996; 15(6): 533-540.
145. Barbaccia ML, Roscetti G, Trabucchi M, et al. The effects of inhibitors of GABAergic transmission and stress on brain and plasma allopregnanolone concentrations. Br J Pharmacol. 1997; 120(8): 1582-1588.
146. Kehoe P, Mallinson K, McCormick CM, Frye CA. Central allopregnanolone is increased in rat pups in response to repeated, short episodes of neonatal isolation. Brain Res Dev Brain Res. 2000; 124(1-2): 133-136.
147. Djebaili M, Guo Q, Pettus EH, Hoffman SW, Stein DG. The neurosteroids progesterone and allopregnanolone reduce cell death, gliosis, and functional deficits after traumatic brain injury in rats. J Neurotrauma. 2005; 22(1): 106-118.
148. Sayeed I, Parvez S,Wali B, Siemen D, Stein DG. Direct inhibition of the mitochondrial permeability transition pore: A possible mechanism for better neuroprotective effects of allopregnanolone over progesterone. Brain Res. 2009; 1263: 165-173.
149. He J, Evans C-O, Hoffman SW, Oyesiku NM, Stein DG. Progesterone and allopregnanolone reduce inflammatory cytokines after traumatic brain injury. Exp Neurol. 2004; 189(2): 404-412.
150. Bixo M, Andersson A, Winblad B, Purdy RH, Bäckström T. Progesterone, 5?-pregnane-3,20-dione and 3?-hydroxy-5?-pregnane-20-one in specific regions of the human female brain in different endocrine states. Brain Res. 1997; 764(1-2): 173-178.
151. Akwa Y, Purdy RH, Koob GF, Britton KT. The amygdala mediates the anxiolytic-like effect of the neurosteroid allopregnanolone in rat. Behav Brain Res. 1999; 106(1-2): 119-125.
152. Epperson CN, Gueorguieva R, Czarkowski KA, et al. Preliminary evidence of reduced occipital GABA concentrations in puerperal women: A 1H-MRS study. Psychopharmacology (Berl). 2006; 186(3): 425-433.
153. Schiller CE, Schmidt PJ, Rubinow DR. Allopregnanolone as a mediator of affective switching in reproductive mood disorders. Psychopharmacology (Berl). 2014; 231(17): 3557-3567.
154. Tarantino LM, Sullivan PF, Meltzer-Brody S. Using animal models to disentangle the role of genetic, epigenetic, and environmental influences on behavioral outcomes associated with maternal anxiety and depression. Front Psychiatry. 2011; 2: 44.
155. Maguire J, Mody I. GABAAR plasticity during pregnancy: Relevance to postpartum depression. Neuron. 2008; 59(2): 207-213.
156. Maguire JL, Stell BM, Rafizadeh M, Mody I. Ovarian cycle-linked changes inGABA(A) receptorsmediating tonic inhibition alter seizure susceptibility and anxiety. Nat Neurosci. 2005; 8(6): 797-804.
157. Maguire J, Ferando I, Simonsen C, Mody I. Excitability changes related to GABAA receptor plasticity during pregnancy. J Neurosci. 2009; 29(30): 9592-9601.